Immunotherapy Insights call for papers from Dr John Barrett

Dear friends,

I invite you to submit your papers and reviews to Imunotherapy Insights. We are a peer reviewed, open access journal, published by Libertas Academica. We publish on a broad spectrum of immunotherapeutic topics, covering cellular immunotherapy, vaccines and cytokine treatment. I can promise you expert revew from an internationally recognized panel, rapid turn around, and early publication of your findings.

Immunotherapy is a fast-developing area of research and clinical practice, making possible new treatments for hematological malignancies, cancer, and autoimmune diseases. Immunotherapy Insights will be read by your peers whether scientists or clinicians in the field of immune-based treatments cancer research and autoimmune diseases. In this fast developing area of research there are only a few journals specifically targeting immunotherapy.

If you have papers or reviews that merit sharing rapidly with the scientific community then remember Imunotherapy Insights is one of the few routes to rapid publication. I look forward to your contributions to this new online journal!

What is the advantage to you of publishing in Immunotherapy Insights?

• Full open access: everyone can read your article and you retain copyright in it
• Publishing decision within 2 weeks of submission
• Your paper will not be rejected due to lack of space and will be published immediately on acceptance
• Prompt and fair peer review from two expert peer reviewers
• Frequent updates on your paper’s status
• Friendly responsive staff

Aims and scope:

Imunotherapy Insights is a journal that publishes papers on all aspects of manipulation of the immune system to treat disease or allergies.

What a previous author said:

"I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."

In summary:

The advantages of a younger journal such as Imunotherapy Insights are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Yours sincerely,

Dr John Barrett
Editor-in-Chief
Imunotherapy Insights